Proton Therapy Pediatric denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for proton therapy pediatric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Pediatric Proton Therapy

Proton beam therapy is a high-cost, high-complexity radiation modality that Aetna subjects to prior authorization review for all patient populations, including pediatric patients. A prior-auth-required denial typically means either that treatment was initiated or billed before authorization was obtained, or that the authorization request was submitted but denied because the supporting documentation did not satisfy Aetna's clinical criteria at the time of review. In pediatric oncology, where urgency is common, prior authorization timelines can create tension with clinical need — and the appeals process exists precisely to address that tension.

## Why This Denial Is Appealable

If the denial is a retrospective denial because treatment proceeded before authorization was in place, an appeal can succeed if the clinical urgency is documented and the care met the plan's coverage criteria — emergency and urgent-care provisions may apply. If the denial was a prospective authorization denial, the standard appeal process applies: the goal is to submit documentation sufficient to satisfy each of Aetna's clinical criteria. Either way, the underlying medical-necessity standard is what the appeal must ultimately address.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Clearly identify whether this is a prospective authorization denial or a retrospective denial, as the arguments differ.
• Expedited review (ACA §2719): If treatment is pending and delay would jeopardize the child's health, request expedited internal review — Aetna must respond within 72 hours. Request expedited external review simultaneously.
• External review: After internal denial, an IRO can independently review whether the plan's authorization criteria were met.
• ERISA §503: Requires the plan to provide the criteria applied and allow submission of additional clinical information.
• External review window: Initiate within four months of the final internal denial.

## Documentation to Gather

• Authorization request records: Copies of all prior authorization submissions, including dates, submitted documents, and any plan acknowledgments.
• Urgency documentation: If treatment was urgent or emergent, chart documentation of the clinical urgency and any communications with Aetna about expedited review.
• Treating radiation oncologist's letter: Detailed medical-necessity letter addressing Aetna's clinical criteria for proton therapy in pediatric patients.
• Complete oncologic workup: Pathology, imaging, staging, tumor board recommendation, and treatment plan.
• Dosimetric comparison: Quantitative treatment planning comparison supporting the selection of proton therapy.
• Timeline documentation: A clear chronology of diagnosis, authorization request, and treatment decisions.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy for proton beam therapy — available in the denial letter or by request from Aetna's utilization management department. List each clinical criterion required for authorization. For each criterion, provide the exact corresponding chart fact with the document name, date, and author. If the denial was retrospective, add a section documenting the clinical urgency and citing the plan's emergency or urgent-care provisions. A complete, organized submission that closes every documentation gap identified in the original denial is the most effective path to approval.